What is NDC 70954-228?

70954-228 is the product NDC for Methsuximide, Methsuximide 300 mg/1 capsule, listed with the FDA by ANI Pharmaceuticals, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

ANI Pharmaceuticals, Inc., NDC labeler code 70954. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Methsuximide?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Methsuximide NDC 70954-228 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)70954-228Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70954-0228Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70954-228-10	70954022810	100 CAPSULE in 1 BOTTLE (70954-228-10)Marketed from May 1, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Methsuximide
Generic name (nonproprietary): methsuximide
Active ingredients: Methsuximide — 300 mg/1
Dosage form: Capsule
Route: Oral
Labeler: ANI Pharmaceuticals, Inc.NDC labeler code 70954
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 217213
Marketing start: May 1, 2023
Listing expires: Dec 31, 2026
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 70954-228_5138e347-665b-4dd6-b9f8-12f4a807ed4eSPL ID 5138e347-665b-4dd6-b9f8-12f4a807ed4eSPL set ID 5138e347-665b-4dd6-b9f8-12f4a807ed4eRxCUI 197949UNII 0G76K8X6C0UPC 0370954228103
Pharmacologic class: Anti-epileptic Agent

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470954022810 followed by a unit qualifier and the quantity

Package 70954-0228-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 3, 2023.

Indications (excerpt from the label)

INDICATIONS & USAGE Methsuximide is indicated for the control of absence (petit mal) seizures that are refractory to other drugs.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 70954-228

What is NDC 70954-228?: 70954-228 is the product NDC for Methsuximide, Methsuximide 300 mg/1 capsule, listed with the FDA by ANI Pharmaceuticals, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Methsuximide.
What is the active ingredient?: Methsuximide.
Who is the labeler?: ANI Pharmaceuticals, Inc., NDC labeler code 70954. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Methsuximide?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.